| Identification | Back Directory | [Name]
Propanamide, N-[2-[2-(2-aminoethyl)-1-pyrrolidinyl]-2-oxoethyl]-2-[3-[(3R)-3-[[[cyclopropyl[[4-(1H-pyrazol-4-yl)phenyl]methyl]amino]carbonyl]amino]-1-piperidinyl]phenoxy]-2-methyl- | [CAS]
3027905-74-1 | [Synonyms]
Propanamide, N-[2-[2-(2-aminoethyl)-1-pyrrolidinyl]-2-oxoethyl]-2-[3-[(3R)-3-[[[cyclopropyl[[4-(1H-pyrazol-4-yl)phenyl]methyl]amino]carbonyl]amino]-1-piperidinyl]phenoxy]-2-methyl- | [Molecular Formula]
C37H50N8O4 | [MOL File]
3027905-74-1.mol | [Molecular Weight]
670.85 |
| Chemical Properties | Back Directory | [Boiling point ]
996.8±65.0 °C(predicted) | [density ]
1.29±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
13.52±0.20(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models[1]. | [References]
[1] Zhu W, et al., Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells. J Med Chem. 2024 Jun 24. DOI:10.1021/acs.jmedchem.3c02079 |
|
|